GLP-1 Agonists May Reduce Fracture Risk in Type 2 Diabetes

A new analysis published in JAMA Network Open suggests GLP-1 receptor agonists, commonly used for type 2 diabetes, are associated with a lower risk of fragility fractures. This finding challenges prior assumptions that rapid weight loss from these medications might increase fracture risk. The study indicates potential benefits beyond glycemic control and weight loss, particularly for individuals with metabolic stress.